According to a new report by Polaris Market Research, the global Biomarkers market was valued at USD 63.07 Billion in 2025 and is projected to reach USD 147.46 Billion by 2034, expanding at a CAGR of 9.84% over the forecast period. Growth is underpinned by rising chronic disease prevalence, expanding genomics and proteomics advancement, and accelerating AI-driven biomarker discovery across key end-use industries.

What Is Driving Biomarkers Market Growth?

Demand is climbing as the rising global prevalence of chronic diseases converges with rapid advancements in genomics and proteomics. Pharmaceutical and diagnostic companies are prioritizing precision medicine, pushing biomarker adoption across drug discovery, clinical diagnostics, and personalized treatment planning worldwide. Polaris analysts note that expanding companion diagnostics and AI-driven analytics position the segment for sustained double-digit growth through 2034, with clinical diagnostics emerging as the largest application contributor and personalized medicine posting the fastest incremental gains.

Key Trends Shaping the Biomarkers Industry

AI and Big Data Analytics in Biomarker Research

Machine learning is accelerating biomarker identification and validation from genomic, proteomic, and clinical datasets, weaving deeper technology advancement into precision medicine pipelines.

Regulatory Support for Biomarker-Based Drug Development

Fast-track designations and qualification programs from agencies such as the FDA and EMA are strengthening the regulatory landscape for biomarker-guided clinical trials and companion diagnostics.

Expansion of Multi-Omics and Companion Diagnostics

Growing integration of genomics, proteomics, and metabolomics data is reshaping the competitive landscape, fueling demand for validated, disease-specific biomarker panels.

Market Segmentation: Breaking Down the Biomarkers Market

Polaris segments the Biomarkers market by type, research area, technology, disease indication, application, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Type

The Efficacy Biomarkers segment led the market in 2025, holding 45.0% of revenue on the strength of its use in evaluating drug responses and monitoring therapeutic outcomes during clinical trials. The Validation Biomarkers segment is projected to grow fastest, at a CAGR of 10.50% through 2034, as demand for reproducible, standardized biomarker data rises across regulatory settings.

By Research Area

Genomics dominated the market with a 45.0% revenue share in 2025, driven by widespread use of gene panels and next-generation sequencing. The Proteomics segment is expected to exhibit the fastest growth rate of 9.80% through 2034, signaling where near-term demand around "protein-based biomarkers" is shifting.

By Technology

Immunoassays accounted for a substantial 25.0% share in 2025 due to their sensitivity, ease of implementation, and cost-effectiveness. Next-Generation Sequencing (NGS) is projected to witness the fastest growth of 10.49% through 2034, driven by falling sequencing costs and expanding genomic databases.

By Disease Indication

Among disease indications, Cancer captured the largest share at 35.0% in 2025, while Neurological Disorders are expected to post the strongest incremental growth at a CAGR of 9.80%, reflecting rising Alzheimer's and Parkinson's research investment.

Explore The Complete Comprehensive Report Here:

https://www.polarismarketresearch.com/industry-analysis/biomarkers-market 

Regional Outlook: Where Is Biomarkers Growing Fastest?

North America led the market in 2025 on the back of a strong biopharmaceutical and diagnostic-company presence, accounting for 42.0% of global revenue, while Asia Pacific is expected to post the fastest CAGR of 11.50% through 2034, driven by expanding healthcare infrastructure and rising chronic disease prevalence. Within North America, the U.S. remains the largest single market, capturing 90.0% of regional revenue; within Asia Pacific, China and India are the primary growth engines. Europe rounds out the top three with a 28.0% share, supported by Horizon Europe funding and strong academic-industry collaboration in Germany, France, and the Netherlands.

Competitive Landscape: Leading Biomarkers Companies

Key players profiled in the report include Abbott Laboratories, Agilent Technologies, BioMérieux SA, F. Hoffmann-La Roche Ltd, Illumina, Inc., and Thermo Fisher Scientific, Inc., who are focusing on multi-omics integration, AI-driven analytics, and strategic collaborations to strengthen market position across the Efficacy Biomarkers and Clinical Diagnostics segments outlined above. Recent moves include Alamar Biosciences' launch of the NULISAseq Neuro 220 Panel and the Viromarkers project's cross-sectoral partnership to validate virus-related biomarkers, both aimed at deepening share in precision diagnostics.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching biomarkers market entry, this report benchmarks market share, segment-level pricing, and forecast data — by type, research area, technology, disease indication, application, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking personalized medicine as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Bathroom Cabinets Market

Video Intercom Devices Market

Prostate Health Market

Organic Food And Beverages Market

Precision Engineering Machines Market

Precision Engineering Machines Market

Optical Coherence Tomography (Oct) Market

Radio-Frequency Identification (RFID) Market

Disinfectant Spray Market